<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02660294</url>
  </required_header>
  <id_info>
    <org_study_id>PRP-IVF</org_study_id>
    <nct_id>NCT02660294</nct_id>
  </id_info>
  <brief_title>Intrauterine Autologous PRP Infusion Compared to HRT for Enhancing Endometrial Thickness in Patients Undergoing ICSI</brief_title>
  <official_title>Intrauterine Autologous Platelet -Enriched Plasma Infusion Compared to Hormonal Replacement Therapy for Enhancing Endometrial Thickness in Patients Undergoing ICSI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Successful embryo implantation needs an optimum embryonic development with a receptive
      endometrium. Endometrial thickness is an independant factor for endometrial receiptivity. The
      aim of that trial is to assess the benefecial effect of platelt rich plasma in copmarison
      with standard hormonal therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single blinded randomized trial comparing the effect of of platlet rich plasma
      versus hormonal therapy on endometrial thickness and consequently endometrial receptivity.
      The primary endpoint of this trial is clinical pregnancy rate.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>endometrial thickness in mm</measure>
    <time_frame>72 hours</time_frame>
    <description>using transvaginal ultrasound to measure endometrial thickness in mm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical pregnancy rate</measure>
    <time_frame>4 weeks after embryo transfer</time_frame>
    <description>using transvaginal ultrasound to detect fetal cardiac activity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Platlet rich plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For those with endometrial thickness less than 7 mm intrauterine injection of platlet rich plasma (PRP) for enhancing endometrial thickness and receptivity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hormone replacement therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Oral intake of estradiol valerate for those with endometrial thickness less than 7 mm will improve endometrial receptivity</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>platlet rich plasma</intervention_name>
    <description>Platelet-rich plasma (PRP) is prepared from fresh whole blood which is collected from a peripheral vein, stored in acid citrate dextrose solution A (ACD-A) anticoagulant and processed to increase platelets by separating various components of blood</description>
    <arm_group_label>Platlet rich plasma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients undergoing ICSI

          -  endometrial thickness less than 7 mm on early follicular phase

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>RASHA DR MEDHAT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>rasha Dr medhat, MD</last_name>
    <phone>1224448449</phone>
    <phone_ext>0020</phone_ext>
    <email>RASHAMEDHAT30@GMAIL.COM</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ahmed DR kotb, MD</last_name>
    <phone>1008681999</phone>
    <phone_ext>0020</phone_ext>
    <email>ahmedmkotp@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rasha</name>
      <address>
        <city>Cairo</city>
        <state>Al Qahirah</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rasha M Abdul-hady, MD</last_name>
      <phone>1224448449</phone>
      <phone_ext>0020</phone_ext>
      <email>rashamedhat30@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>ahmed M kotb, MD</last_name>
      <phone>1004711414</phone>
      <phone_ext>0020</phone_ext>
      <email>ahmedmkotp@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2016</study_first_submitted>
  <study_first_submitted_qc>January 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2016</study_first_posted>
  <last_update_submitted>March 19, 2016</last_update_submitted>
  <last_update_submitted_qc>March 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>rasha medhat abdul-hady</investigator_full_name>
    <investigator_title>DR. Rasha Medhat Abdul-hady</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

